Progress of anticoagulation therapy in atrial fibrillation;Avances en el tratamiento anticoagulante de la fibrilación auricular

Medicina Clinica

Volumn 145, Issue 3, 2015, Pages 124-130

  Hernández Olmedo, Miguel ^a   Suárez Fernández, Carmen ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Atrial fibrillation; Direct action anticoagulants; Intracranial hemorrhage; New oral anticoagulants; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); COMPLICATION; STROKE; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; FACTOR XA INHIBITORS; HUMANS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84937395106     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2014.07.018     Document Type: Review

References (54)

1. J.M. García-Acuña, J.R. González-Juanatey, E. Alegría Ezquerra, I. González Maqueda, and J.L. Listerri La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999 Rev Esp Cardiol 55 2002 943 952
2. A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, J.V. Selby, and et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and risk factors in atrial fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
3. L. Cea-Calvo, J. Redón, J.V. Lozano, C. Fernández-Pérez, J.C. Martí-Canales, J.L. Llisterri Investigators of the PREV-ICTUS Study Prevalence of atrial fibrillation in the Spanish population aged 60 years or more. The PREV-ICTUS study Rev Esp Cardiol 60 2007 616 624
4. I. Savalieva, and J. Camm Update on atrial fibrillation: Part I Clin Cardiol 31 2008 55 62
5. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: The Framingham Study Stroke 22 1991 983 988
6. J.A. Reiffel Atrial fibrillation and stroke: Epidemiology Am J Med 127 2014 e15 e16
7. L.M. Christensen, D.W. Krieger, S. Hojberg, O.D. Pedersen, F.M. Karlsen, M.D. Jacobsen, and et al. Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study Eur J Neurol 21 2014 884 889
8. M. Lamassa, A. di Carlo, G. Pracucci, A.M. Basile, G. Trefoloni, P. Vanni, and et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: Data from a multicenter multinational hospital-based registry (The European Community Stroke Project) Stroke 32 2001 392 398
9. S.E. Wolowacz, M. Samuel, V.K. Brennan, J.G. Jasso-Mosqueda, and I.C. van Gelder The cost of illness of atrial fibrillation: A systematic review of the recent literature Europace 13 2011 1375 1385
10. Stroke Prevention in Atrial Fibrillafion Study. Final results Circulation 84 1991 527
11. M.D. Ezekowitz, S.L. Bridgers, K.E. James, N.H. Carliner, C.L. Colling, C.C. Gornick, and et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators N Eng J Med 327 1992 1406 1412
12. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
13. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
14. J.J. You, D.E. Singer, P.A. Howard, D.A. Lane, M.H. Eckman, M.C. Fang, and et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl 2012 e531S e575S
15. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation Chest 137 2010 263 272
16. A.J. Camm, G.Y. Lip, R. de Caterina, I. Savelieva, D. Atar, S.H. Hohnloser ESC Committee for Practice Guidelines (CPG) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
17. M. Rodríguez-Mañero, A. Cordero, V. Bertomeu-González, J. Moreno-Arribas, V. Bertomeu-Martínez, P. Mazón, and et al. Impacto de los nuevos criterios para el tratamiento anticoagulante de la fibrilación auricular Rev Esp Cardiol 64 2011 649 653
18. J.B. Olesen, G.Y. Lip, M.L. Hansen, P.R. Hansen, J.S. Tolstrup, J. Lindhardsen, and et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study BMJ 342 2011 d124
19. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey Chest 138 2010 1093 1100
20. L. Gorin, L. Fauchier, E. Nonin, B. Charbonnier, D. Babuty, and G.Y.H. Lip Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter. Implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project Chest 140 2011 911 917
21. Y. Wan, C. Heneghan, R. Perera, N. Roberts, J. Hollowell, P. Glasziou, and et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review Circ Cardiovasc Qual Outcomes 1 2008 84 91
22. A.K. Kakkar, I. Mueller, J.P. Bassand, D.A. Fitzmaurice, S.Z. Goldhaber, S. Goto, and et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Perspectives from the international, observational, prospective GARFIELD registry PLoS One 8 2013 e63479
23. B.I. Eriksson, D.J. Quinlan, and J.I. Weitz Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development Clin Pharmacokinet 48 2009 1 22
24. F. Schiele, J. van Ryn, K. Canada, C. Newsome, E. Sepulveda, J. Park, and et al. A specific antidote for dabigatran: Functional and structural characterization Blood 121 2013 3554 3562
25. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
26. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
27. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
28. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, and et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
29. C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, M.D. Ezekowitz, and et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials Lancet 383 2014 955 962
30. J.W. Eikelboom, L. Wallentin, S.J. Connolly, M. Ezekowitz, J.S. Healey, J. Oldgren, and et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
31. M. Hori, M. Matsumoto, N. Tanahashi, S.I. Momomura, S. Uchiyama, S. Goto, and et al. Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age Circ J 78 2014 1349 1356
32. S. Halvorsen, D. Atar, H. Yang, R. de Caterina, C. Erol, D. Garcia, and et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial Eur Heart J 35 2014 1864 1872
33. Z. Hijazi, S.H. Hohnloser, J. Oldgren, U. Andersson, S.J. Connolly, J.W. Eikelboom, and et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Circulation 129 2014 961 970
34. M. Hori, M. Matsumoto, N. Tanahashi, S. Momomura, S. Uchiyama, S. Goto, and et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Subanalysis of J-ROCKET AF for patients with moderate renal impairment Circ J 77 2013 632 638
35. S.H. Hohnloser, Z. Hijazi, L. Thomas, J.H. Alexander, J. Amerena, M. Hanna, and et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial Eur Heart J 33 2012 2821 2830
36. L.H. Rasmussen, T.B. Larsen, T. Graungaard, F. Skjøth, and G.Y. Lip Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis BMJ 345 2012 e7097
37. P. Sardar, S. Chatterjee, W.C. Wu, E. Lichstein, J. Ghosh, S. Aikat, and et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons PLoS One 8 2013 e77694
38. A. Gómez-Outes, A.I. Terleira-Fernández, G. Calvo-Rojas, M.L. Suárez-Gea, and E. Vargas-Castrillón Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of subgroups Thrombosis 2013 2013 640723
39. R. Nagarakanti, M.D. Ezekowitz, J. Oldgren, S. Yang, M. Chernick, T.H. Aikens, and et al. Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion Circulation 123 2011 131 136
40. J.P. Piccini, S.R. Stevens, Y. Lokhnygina, M.R. Patel, J.L. Halperin, D.E. Singer, and et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 61 2013 1998 2006
41. G. Flaker, R.D. Lopes, S.M. al-Khatib, A.G. Hermosillo, S.H. Hohnloser, B. Tinga, and et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: Insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) J Am Coll Cardiol 63 2014 1082 1087
42. A. Banerjee, D.A. Lane, C. Torp-Pedersen, and G.Y. Lip Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study Thromb Haemost 107 2012 584 589
43. J.C. Ho, A.M. Chang, B.P. Yan, C.M. Yu, Y.Y. Lam, and V.W. Lee Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: Experience in Hong Kong Clin Cardiol 35 2012 E40 E45
44. F. Laliberté, M. Cloutier, W.W. Nelson, C.I. Coleman, D. Pilon, W.H. Olson, and et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients Curr Med Res Opin 30 2014 1317 1325
45. T.B. Larsen, L.H. Rasmussen, F. Skjøth, K.M. Due, T. Callréus, M. Rosenzweig, and et al. Efficacy and safety of dabigatran etexilate and warfarin in 'real-world' patients with atrial fibrillation: A prospective nationwide cohort study J Am Coll Cardiol 61 2013 2264 2273
46. R. Sørensen, G. Gislason, C. Torp-Pedersen, J.B. Olesen, E.L. Fosbøl, M.W. Hvidtfeldt, and et al. Dabigatran use in Danish atrial fibrillation patients in 2011: A nationwide study BMJ Open 3 2013 e002758
47. S. Shore, E.P. Carey, M. Turakhia, C. Jackevicius, F. Cunnigham, and A.E. Baron Patterns of Adherence to Dabigatran and its Association with Outcomes AHA Scientific Sessions 2013 Presentation n° 16864
48. Informe de posicionamiento terapéutico UT/V4/23122013. Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales (NACO) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular. Agencia Española de Medicamentos y Productos Sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad. Dic 2013.
49. M. Krejczy, J. Harenberg, S. Marx, K. Obermann, L. Frölich, M. Wehling, and et al. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries J Thromb Thrombolysis 37 2014 507 523
50. A.R. Harrington, E.P. Armstrong, P.E. Nolan Jr., and D.C. Malone Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Stroke 44 2013 1676 1681
51. D. Coyle, K. Coyle, C. Cameron, K. Lee, S. Kelly, S. Steiner, and et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation Value Health 16 2013 498 506
52. G.Y. Lip, T. Kongnakorn, H. Phatak, A. Kuznik, T. Lanitis, L.Z. Liu, and et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation Clin Ther 36 2014 192 210
53. B.L. Limone, W.L. Baker, J. Kluger, and C.I. Coleman Novel anticoagulants for stroke prevention in atrial fibrillation: A systematic review of cost-effectiveness models PLoS One 8 2013 e62183
54. B.S. Stambler A new era of stroke prevention in atrial fibrillation: Comparing a new generation of oral anticoagulants with warfarin Int Arch Med 6 2013 46